:: Library Catalog

Buchumschlag

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	Pranab M. Barman
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2026
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	https://onlinelibrary.wiley.com/doi/10.1111/apt.70549
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Editorial: Steroid‐Induced Diabetes in Autoimmune Hepatitis—A Call for Treatment Optimisation. Authors' Reply
von: Sarah Flatley
Veröffentlicht: (2026)

Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study
von: Pinelopi Arvaniti, et al.
Veröffentlicht: (2025)

Letter on ‘Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study’
von: Muhammad Ibrahim Khalil, et al.
Veröffentlicht: (2025)

Editorial: Addressing Unmet Needs and Socioeconomic Disparity in Patients With Autoimmune Hepatitis
von: Seren Gedallovich, et al.
Veröffentlicht: (2024)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
von: Pinelopi Arvaniti, et al.
Veröffentlicht: (2025)

Autoimmune Hepatitis and Vitamin D Deficiency: A Nationwide Perspective
von: Yassine Kilani, et al.
Veröffentlicht: (2024)

Editorial: High Baseline ALT Level Confers Risk of Hepatic Adverse Events During Immune Checkpoint Inhibitors Treatment: A Call for Caution
von: Ze‐Hua Zhao, et al.
Veröffentlicht: (2025)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2025)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection—Authors' Reply
von: Yu‐Ping Chang, et al.
Veröffentlicht: (2025)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
von: Lukas Burghart, et al.
Veröffentlicht: (2026)

Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
von: Yu‐Ping Chang, et al.
Veröffentlicht: (2025)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis
von: Ganesh Bhat, et al.
Veröffentlicht: (2026)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis. Authors' Reply
von: Amol N. Patil, et al.
Veröffentlicht: (2026)

Diabetes Mellitus is a Risk Factor for Hepatic Encephalopathy Following Transjugular Intrahepatic Portosystemic Shunt
von: Michelle Spaan, et al.
Veröffentlicht: (2025)

Clinical Trial: Long Versus Short Tapering of Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis—A Randomised Controlled Trial
von: Ankit Kumar, et al.
Veröffentlicht: (2026)

Letter: Steroid Tapering—Is Shorter Duration Better?
von: Juntao Lu, et al.
Veröffentlicht: (2026)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors
von: Stefan Mauss
Veröffentlicht: (2025)

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
von: Yi‐Ping Hung, et al.
Veröffentlicht: (2024)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
von: Ying‐Nan Tsai, et al.
Veröffentlicht: (2025)

Editorial: Hepatitis C virus eradication improves skeletal muscle mass
von: Catherine Jia Lin Tian, et al.
Veröffentlicht: (2024)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy
von: Yu Jun Wong
Veröffentlicht: (2025)

Editorial: Beyond Viral Eradication—Scrutinising Outcomes After Hepatitis C Cure
von: Wei‐Fan Hsu, et al.
Veröffentlicht: (2025)

Editorial: Chronic Hepatitis B at the Intersection of Immigration, Acculturation and Social Determinants of Health
von: Thomas Hoang, et al.
Veröffentlicht: (2025)

Editorial: Low‐Level Viraemia in Chronic Hepatitis B—A Benign State or Missed Opportunity?
von: Miriam T. Levy
Veröffentlicht: (2026)

Letter : Is Short Tapering of Steroids in Moderate to Severely Active Ulcerative Colitis Really Inferior to a Long Steroid Taper, or Just Underpowered to Reach a Definitive Conclusion?
von: Hariti Saluja, et al.
Veröffentlicht: (2026)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy—Authors' Reply
von: Tanat Saeoui, et al.
Veröffentlicht: (2025)

Editorial: When Yeast Turns Beast—Unmasking an Overlooked Threat in Alcohol‐Related Hepatitis
von: Maaz Arif, et al.
Veröffentlicht: (2025)

Editorial: Hepatitis C virus eradication improves skeletal muscle mass—Authors' reply
von: Marta Paula Pereira Coelho, et al.
Veröffentlicht: (2024)

Letter: Steroid Tapering in Ulcerative Colitis: The Importance of Disease Severity and Maintenance Therapy
von: Rónán O'Connor, et al.
Veröffentlicht: (2026)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation
von: Thanawin Pramotedham, et al.
Veröffentlicht: (2026)

Editorial: Terlipressin Induced Bradycardia
von: Nancy Reau, et al.
Veröffentlicht: (2025)

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B—Authors' Reply
von: Jian Wang, et al.
Veröffentlicht: (2025)

Editorial: Hepatitis D Screening—DAS (Delta Virus Awareness and Screening) Approach in Primary Care
von: Noreen Singh, et al.
Veröffentlicht: (2025)

Editorial: Chronic Hepatitis Delta—We Need More Screening to Improve Knowledge on the Natural History
von: J. Ventre, et al.
Veröffentlicht: (2025)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C
von: Shun‐Ichi Wakabayashi, et al.
Veröffentlicht: (2026)

Editorial: When Yeast Turns Beast—Unmasking an Overlooked Threat in Alcohol‐Related Hepatitis. Authors' Reply
von: Vincent Mallet, et al.
Veröffentlicht: (2025)

Letter: Trajectories of Hepatic Function Markers Enable Early Prediction of Hepatic Recompensation
von: Benedikt Silvester Hofer, et al.
Veröffentlicht: (2026)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation. Authors' Reply
von: Mary Yue Wang, et al.
Veröffentlicht: (2026)

Letter: Tenofovir Alafenamide—The “Star of Potential” for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials
von: YaoYao Dai, et al.
Veröffentlicht: (2025)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' Reply
von: Pei‐Chien Tsai, et al.
Veröffentlicht: (2026)